Pancreatic Cancer Research

ResearcherVeterans Health AdministrationActive in the last 2 years

Volkan N. Adsay

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1308-3701; OpenAlex author ID A5023965369. Sources: OpenAlex.

Their work

Papers
33 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
141
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 5 papers · 2014: 4 papers · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 5 papers

Papers 33

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. "Simple Mucinous Cysts" associated with pancreatic ductal adenocarcinoma: clinicopathologic and radiologic characterization of an enigmatic cyst and additional… Last author DOI 10.1007/s00428-026-04705-w↗
  3. "Horses out of the barn": pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification for accura… Last author DOI 10.1111/his.70099↗
  4. Pearls and Pitfalls of Real-Life Molecular Testing on Fine-Needle Aspiration and Core Biopsy in Pancreatic Adenocarcinoma Practice. Co-author DOI 10.1159/000549794↗
  5. The role of artificial intelligence in postoperative clinical decision-making for pancreatic cancer: a pilot study. Co-author DOI 10.1016/j.hpb.2025.07.643↗
  6. Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2024.12.005↗
  7. Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors. Co-author DOI 10.1016/j.semcancer.2025.06.001↗
  8. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  9. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  10. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  11. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Last author DOI 10.1097/pas.0000000000001853↗
  12. Pathology and Molecular Characteristics of Pancreatic Cancer. First author DOI 10.1016/j.soc.2021.06.003↗
  13. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  14. Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cro… Co-author DOI 10.1097/pas.0000000000001723↗
  15. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Co-author DOI 10.1136/gutjnl-2020-320726↗
  16. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  17. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  18. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Co-author DOI 10.1002/jso.24317↗
  19. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Editio… Last author DOI 10.1245/s10434-016-5093-7↗
  20. Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Co-author DOI 10.18632/oncotarget.10514↗
  21. High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2014.11.004↗
  22. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TN… Last author DOI 10.1245/s10434-015-4861-0↗
  23. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Co-author DOI 10.1038/onc.2013.488↗
  24. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  25. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-1996↗
  26. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Co-author DOI 10.1158/1078-0432.ccr-13-1239↗
  27. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.28144↗
  28. Histopathologic assessment of pancreatic cancer: does one size fit all? Last author DOI 10.1002/jso.23194↗
  29. Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10620-012-2387-x↗
  30. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.08.002↗
  31. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Co-author DOI 10.1038/modpathol.2013.71↗
  32. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. Co-author DOI 10.1172/jci59227↗
  33. Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth? Co-author DOI 10.1111/j.1477-2574.2011.00366.x↗

Closest collaborators

The 25 strongest of 141 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Olca Baştürk · 9 shared papers, 2015–2026 · strength 1.19
  2. Burcu Saka · 10 shared papers, 2013–2026 · strength 0.80
  3. Michelle Dian Reid · 6 shared papers, 2013–2026 · strength 0.76
  4. Pelin Bağcı · 5 shared papers, 2013–2026 · strength 0.64
  5. Cisel A. Mericoz · 2 shared papers, 2026 · strength 0.63
  6. Bassel F. El‐Rayes · 10 shared papers, 2013–2026 · strength 0.59
  7. Alyssa M. Krasinskas · 6 shared papers, 2013–2026 · strength 0.59
  8. Shishir Kumar Maithel · 9 shared papers, 2013–2026 · strength 0.55
  9. Claudio Luchini · 5 shared papers, 2021–2022 · strength 0.54
  10. David A. Kooby · 9 shared papers, 2011–2026 · strength 0.54
  11. Deyali Chatterjee · 4 shared papers, 2021–2024 · strength 0.48
  12. Huamin Wang · 4 shared papers, 2021–2024 · strength 0.46
  13. Iréne Esposito · 4 shared papers, 2021–2024 · strength 0.46
  14. Chiara Corradi · 2 shared papers, 2025 · strength 0.45
  15. Daniele Campa · 2 shared papers, 2025 · strength 0.45
  16. Manuel Gentiluomo · 2 shared papers, 2025 · strength 0.45
  17. Juan Manuel Sarmiento · 6 shared papers, 2011–2026 · strength 0.45
  18. Lodewijk A.A. Brosens · 4 shared papers, 2021–2022 · strength 0.42
  19. Emrah Alper · 1 shared paper, 2026 · strength 0.39
  20. Pınar Firat · 1 shared paper, 2026 · strength 0.39
  21. Ralph H. Hruban MD · 4 shared papers, 2014–2022 · strength 0.35
  22. Boris V. Janssen · 3 shared papers, 2021–2024 · strength 0.34
  23. Seung‐Mo Hong · 3 shared papers, 2021–2024 · strength 0.34
  24. Anthony James Gill · 3 shared papers, 2021–2024 · strength 0.34
  25. Joanne Verheij · 3 shared papers, 2021–2024 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.